A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
BeiGene
Northwestern University
University of Nebraska
Eastern Cooperative Oncology Group
Mayo Clinic
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
University of Chicago
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Northside Hospital, Inc.
Northside Hospital, Inc.
M.D. Anderson Cancer Center
Northside Hospital, Inc.